Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report.

Literature DB >> 23473447

Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report.

Amber Cardoos¹, Aya Inamori, Gerard Sanacora, Maurizio Fava, David Mischoulon.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2013 PMID： 23473447 PMCID： PMC3681895 DOI： 10.1016/j.psym.2013.02.002

Source DB: PubMed Journal: Psychosomatics ISSN： 0033-3182 Impact factor: 2.386

Keyword Cloud
References

× No keyword cloud information.

20 in total

1. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.

Authors: G J Groeneveld; H J van Kan; J S Toraño; J H Veldink; H J Guchelaar; J H Wokke; L H van den Berg
Journal: J Neurol Sci Date: 2001-10-15 Impact factor: 3.181

2. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro.

Authors: G J Sanderink; B Bournique; J Stevens; M Petry; M Martinet
Journal: J Pharmacol Exp Ther Date: 1997-09 Impact factor: 4.030

3. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.

Authors: Thomas Papouin; Laurent Ladépêche; Jérôme Ruel; Silvia Sacchi; Marilyne Labasque; Marwa Hanini; Laurent Groc; Loredano Pollegioni; Jean-Pierre Mothet; Stéphane H R Oliet
Journal: Cell Date: 2012-08-03 Impact factor: 41.582

4. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Authors: Vladimir Coric; Sarper Taskiran; Christopher Pittenger; Suzanne Wasylink; Daniel H Mathalon; Gerald Valentine; John Saksa; Yu-Te Wu; Ralitza Gueorguieva; Gerard Sanacora; Robert T Malison; John H Krystal
Journal: Biol Psychiatry Date: 2005-09-01 Impact factor: 13.382

Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report.

1. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.

2. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro.

3. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.

4. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

5. Riluzole, a novel antiglutamate, prevents memory loss and hippocampal neuronal damage in ischemic gerbils.

6. NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA/2 mice.

Review 7. Definition and epidemiology of treatment-resistant depression.

8. An open-label trial of riluzole in patients with treatment-resistant major depression.

9. Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons.

10. Riluzole serum concentrations in patients with ALS: associations with side effects and symptoms.